|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.3 USD | -1.75% |
|
+3.16% | -12.36% |
| Apr. 22 | Bernstein Adjusts Price Target on Illumina to $129 From $150 | MT |
| Apr. 22 | Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept | MT |
June 2 (Reuters) -
* MORE THAN 400 GRAIL PATIENTS INCORRECTLY TOLD THEY MAY HAVE CANCER - FT Source text : [https://on.ft.com/3IVT7vX] Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -12.36% | 19.82B | |
| +8.25% | 219B | |
| +8.28% | 187B | |
| +11.23% | 134B | |
| +26.81% | 101B | |
| +0.30% | 62.27B | |
| +16.21% | 52.82B | |
| -1.63% | 47.49B | |
| -1.28% | 40.79B | |
| +12.48% | 39.35B |
ILLUMINA, INC. 
